EOM Pharmaceutical Holdings Provides an Update on Its Lead Drug Candidate EOM613
MONTVALE, N.J., Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a pep
EOM Pharmaceutical Holdings Announces Topline Results of Its COVID-19 Clinical Trial of EOM613 in Brazil
Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J., Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings,
IPO Roundup: Richtech Robotics, Triller and More
EOM Pharmaceuticals Shelves Plans to Uplist Shares, Raise $15M
EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR THERAPEUTICS, LTD.
Company to continue trading on the OTC Markets under the ticker symbol "IMUC" while pursuing listing on a national exchange MONTVALE, N.J., Nov. 10, 2022 /PRNewswire/ -- EOM Pharmaceutical Holdings,
EOM Pharmaceuticals files to uplist to Nasdaq
EOM Pharmaceuticals (OTCPK:IMUC) has filed to uplist from the Pink Sheets to the Nasdaq. As part of the application, EOM would trade on the Nasdaq under the ticker "EOM." EOM (formerly ImmunoCellular
Press Release: EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement Combined company will operate as EOM Pharmaceuticals Holdings, Inc.
ImmunoCellular Therapeutics L, Inst Holders, 3Q 2019 (IMUC)
DJ ImmunoCellular Therapeutics L, Inst Holders, 3Q 2019 (IMUC) The following table shows the largest shareholders in IMMUNOCELLULAR THERAPEUTICS LTD CO (IMUC) for the quarter ended September 3
ImmunoCellular Therapeutics L, Inst Holders, 2Q 2019 (IMUC)
DJ ImmunoCellular Therapeutics L, Inst Holders, 2Q 2019 (IMUC) The following table shows the largest shareholders in IMMUNOCELLULAR THERAPEUTICS LTD CO (IMUC) for the quarter ended June 30, 20
ImmunoCellular Therapeutics L, Inst Holders, 1Q 2019 (IMUC)
DJ ImmunoCellular Therapeutics L, Inst Holders, 1Q 2019 (IMUC) The following table shows the largest shareholders in IMMUNOCELLULAR THERAPEUTICS LTD CO (IMUC) for the quarter ended March 31, 2
ImmunoCellular Therapeutics L, Inst Holders, 4Q 2018 (IMUC)
DJ ImmunoCellular Therapeutics L, Inst Holders, 4Q 2018 (IMUC) The following table shows the largest shareholders in IMMUNOCELLULAR THERAPEUTICS LTD CO (IMUC) for the quarter ended December 31
DJ ImmunoCellular Therapeutics L, Inst Holders, 3Q 2018 (IMUC)
DJ ImmunoCellular Therapeutics L, Inst Holders, 3Q 2018 (IMUC) The following table shows the largest shareholders in IMMUNOCELLULAR THERAPEUTICS LTD CO (IMUC) for the quarter ended September 3
DJ ImmunoCellular Therapeutics Ltd. (IMUC) Halted
DJ ImmunoCellular Therapeutics Ltd. (IMUC) Halted (END) Dow Jones Newswires October 16, 2018 12:28 ET (16:28 GMT) Copyright (c) 2018 Dow Jones & Company, Inc.
BRIEF-Immunocellular Therapeutics Ltd - Anthony Gringeri Resigs From Board And As President And CEO Of Co
Oct 15 (Reuters) - ImmunoCellular Therapeutics Ltd : * IMMUNOCELLULAR THERAPEUTICS LTD - ANTHONY GRINGERI NOTIFIED CO HE RESIGNED FROM BOARD AND AS PRESIDENT AND CEO OF CO, EFFECTIVE AS OF OC
DJ ImmunoCellular Files 8K - Director, Officer or Compensation Filing >IMUC
DJ ImmunoCellular Files 8K - Director, Officer or Compensation Filing >IMUC ImmunoCellular Therapeutics Ltd. (IMUC) filed a Form 8K - Director, Officer or Compensation Filing - with the U.S
*DJ ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stk and Listed Common Stk Warrants
Press Release: ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants ImmunoCellular Therapeutics Announces Delisting and Deregistrat
BRIEF-ImmunoCellular Therapeutics Says Has Been Exploring Strategic Opportunities
Aug 13 (Reuters) - ImmunoCellular Therapeutics Ltd : * IMMUNOCELLULAR THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS * Q2 LOSS PER SHARE $0.01
Press Release: ImmunoCellular Therapeutics -2-
*DJ ImmunoCellular 2Q Loss/Shr 1c >IMUC (MORE TO FOLLOW) Dow Jones Newswires (212-416-2800) August 13, 2018 16:05 ET (20:05 GMT) Press Release: ImmunoCellular Therapeutics Provides Cor
*DJ ImmunoCellular 2Q Loss/Shr 1c >IMUC
*DJ ImmunoCellular 2Q Loss/Shr 1c >IMUC (MORE TO FOLLOW) Dow Jones Newswires (212-416-2800) August 13, 2018 16:05 ET (20:05 GMT) Copyright (c) 2018 Dow Jones & Company, Inc.
DJ ImmunoCellular Therapeutics Ltd, Inst Holders, 2Q 2018 (IMUC)
DJ ImmunoCellular Therapeutics Ltd, Inst Holders, 2Q 2018 (IMUC) The following table shows the largest shareholders in IMMUNOCELLULAR THERAPEUTICS LTD CO (IMUC) for the quarter ended June 30,
No Data